ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Brief description of study
To determine in the context of a randomized trial whether the Event-Free Survival of patients with newly diagnosed high-risk NBL is improved with the addition of I-MIBG during Induction, prior to tandem autologous stem cell transplantation (ASCT).
Clinical Study Identifier: s19-00979
ClinicalTrials.gov Identifier: NCT03126916
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
